Navigation Links
Rhythm Names Keith M. Gottesdiener Chief Executive Officer
Date:11/9/2011

BOSTON, Nov. 9, 2011 /PRNewswire-USNewswire/ -- Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today the appointment of Keith M. Gottesdiener, MD, as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from Merck & Co., Inc., where he served as Vice President and Late-Stage Therapeutic Group Leader, with responsibility for pivotal trials of Merck's products in all therapeutic areas, and previously as head of early-stage clinical development programs.

"The Rhythm clinical candidates are peptides with some important advantages over small molecules for targeting complex pathways that regulate body weight and gastrointestinal function," said Dr. Gottesdiener. "I am excited to join the Rhythm team to develop this pipeline of peptide therapeutics that have real potential to become breakthrough drugs for obesity, diabetes, and GI metabolic disorders."

Over a 16-year career at Merck, Dr. Gottesdiener was responsible for more than 40 major clinical programs and products, including the approval of Gardasil™ (HPV vaccine) and the more recent FDA approval of Victrelis™ (HCV protease inhibitor). Dr. Gottesdiener received an A.B. from Harvard College and an M.D. from the University of Pennsylvania, and he completed his residency and fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs.

"Keith's experience and accomplishments developing innovative, best-in-class drugs—including the diabetes blockbuster, Januvia™—are exceptional," said Bart Henderson, President and co-founder of Rhythm. "He comes to Rhythm at an ideal time, as we advance clinical development of RM-131 for the treatment of diabetic gastroparesis and RM-493 for obesity and diabetes."

"Keith's deep understanding of the clinical development process will greatly enhance Rhythm's novel approach to molecular mechanisms of body weight regulation," said Lou Tartaglia, Ph.D., Rhythm's Chief Scientific Officer and a Partner at Third Rock Ventures. "We are very excited to have attracted such world-class talent to join us in building a great company in the metabolic field."

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Differing structures underlie differing brain rhythms in healthy and ill
2. Dangerous arrhythmia analyzed in a heartbeat
3. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
4. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
5. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
6. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
7. Guam rhino beetles got rhythm
8. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. OXIS International Names David Saloff as Chief Executive Officer
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the ... Charles W. Stellar has been named by the WEDI Board of Directors as WEDI’s ... an executive leader with more than 35 years of experience in healthcare, association management ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... 23, 2016 Oxitec CEO Hadyn ... at 10:15 a.m. ET before the United States House Committee ... mosquitos can play in controlling the spread of the ... virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... a self-limiting gene. Trials in Brazil , ...
(Date:5/20/2016)... Diego, CA (PRWEB) , ... May 20, 2016 , ... ... that 10 of its most experienced veterinary clients have treated over 100 of their ... cutting edge technology to provide the highest level of care for their patients. ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):